Lynne Fahey McGrath

Board Director

Director

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 1 saleNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€4,037

▼ Sales (3 ops.)

€55k

Latest filing published 24 Oct 2025 for Alzamend Neuro, Inc., €59. Read the official filing

Filing timeline

BuySale

Lynne Fahey McGrath

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Lynne Fahey McGrath: trading record in brief

Lynne Fahey McGrath, listed as board member, appears in our data through filings on Alzamend Neuro, Inc. shares, published by SEC (Form 4). Between 13 September 2021 and 23 October 2025, the trades on record add up to 7 filings.

Both buying and selling appear: 1 purchase worth €4,037, against 3 sales worth €55k. The net balance comes to €51k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 option exercises. So far in 2025, the count stands at no purchases and 1 sale.

The latest filing, published on 24 October 2025, reports an open-market sale of €59 in Alzamend Neuro, Inc. The latest purchase dates back some time: it was published 1,305 days ago, on 23 March 2023. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.